![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Article highlights
While Venetoclax stands as the pioneer BCL2 inhibitor, its effectiveness is hampered by the development of resistance mechanisms. Sonrotoclax, characterized by an increased potency as a BCL2 inhibitor emerges as a promising solution to overcome this resistance.
Evidence indicates its efficacy in mature B.–cell malignancies and among patients with acute myeloid leukemia.
Anticipating a promising approach, it is reasonable to consider combining sonrotoclax with other biological therapies like azacitidine for myeloid malignancies and zanubrutinib for Bcell malignancies.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties
Reviewer disclosures
A reviewer on this manuscript has disclosed they have received research funding from Beigene and AbbVie. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.
Correction Statement
This article was originally published with errors, which have now been corrected in the online version. Please see Correction (http://dx.doi.org/10.1080/13543784.2024.2319956)